Foobar

Flow Engineering operates an innovative engineering data platform designed to support agile engineering teams. The platform streamlines the engineering design framework by automating much of the manual execution work, which speeds up the hardware invention process. By providing critical software infrastructure, Flow enables engineers to efficiently develop and iterate on complex drawings, ensuring that teams remain aligned with accurate data across various tools. This integration fosters improved collaboration and enhances overall productivity within engineering projects.

Running Tide is a global ocean health company focused on developing innovative aquaculture techniques to enhance both flavor and nutritional value while addressing climate challenges. By leveraging scientific expertise, the company aims to produce sustainable, low-carbon protein sources. Running Tide employs nature-based interventions to remove carbon from the atmosphere and combat ocean acidification. Its approach involves the design and development of integrated software and hardware systems that utilize photosynthesis, ocean currents, and gravity to sequester carbon in the deep ocean. Through the analysis of ocean data, Running Tide seeks to optimize the use of the Earth's vast marine environments, thereby improving ocean health and amplifying the natural restorative capabilities of the ocean.

HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.

HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.

In 2004, Santtu Parikka founded Fake Production, a VR and gaming studio that won multiple awards for animation. In recent years, as their passion for all things VR/AR has grown, they’ve been drawn to an important challenge: to enable people thousands of miles apart to collaborate effectively in virtual environments, just as they might in a real physical setting. In 2016, Santtu and their CTO Juha Ruistola revealed the first multi-user VR prototypes. These proved an instant hit. A year later, as they crystallized their new mission, vision and strategy, Glue was born. Since then, their 30-strong team has continued to build on their legacy and break new ground in multi-user VR software, developing Glue into the fully-featured virtual collaboration platform they are today.

HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.